Nothing Special   »   [go: up one dir, main page]

PE20150672A1 - Formulaciones de opioides - Google Patents

Formulaciones de opioides

Info

Publication number
PE20150672A1
PE20150672A1 PE2015000092A PE2015000092A PE20150672A1 PE 20150672 A1 PE20150672 A1 PE 20150672A1 PE 2015000092 A PE2015000092 A PE 2015000092A PE 2015000092 A PE2015000092 A PE 2015000092A PE 20150672 A1 PE20150672 A1 PE 20150672A1
Authority
PE
Peru
Prior art keywords
buprenorphine
depot
opioid formulations
salts
opioid
Prior art date
Application number
PE2015000092A
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20150672A1 publication Critical patent/PE20150672A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

La invencion describe una formulacion precursora de deposito que comprende: a) una matriz de liberacion controlada; b) al menos solvente organico que contiene oxigeno; c) al menos 12 % en peso de al menos un agente activo que se selecciona de la buprenorfina y sales de esta, calculada como base libre de buprenorfina. Se proporcionan composiciones de deposito y metodos de tratamiento correspondientes en cuanto al manejo del dolor mediante mantenimiento con opioides y metodos relacionados
PE2015000092A 2012-07-26 2013-07-26 Formulaciones de opioides PE20150672A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
PE20150672A1 true PE20150672A1 (es) 2015-05-21

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000092A PE20150672A1 (es) 2012-07-26 2013-07-26 Formulaciones de opioides

Country Status (20)

Country Link
US (3) US12161640B2 (es)
JP (1) JP6417327B2 (es)
CN (1) CN109010255B (es)
AU (3) AU2016244271B2 (es)
CL (1) CL2015000197A1 (es)
CY (1) CY1124016T1 (es)
DK (1) DK2877155T3 (es)
EA (1) EA034855B1 (es)
ES (1) ES2837803T3 (es)
HK (2) HK1205948A1 (es)
HR (1) HRP20210068T1 (es)
HU (1) HUE053273T2 (es)
IL (3) IL296882A (es)
LT (1) LT2877155T (es)
MX (1) MX361873B (es)
MY (1) MY189481A (es)
NZ (2) NZ704012A (es)
PE (1) PE20150672A1 (es)
PT (1) PT2877155T (es)
SG (2) SG10201703964TA (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2877155T (lt) 2012-07-26 2021-02-25 Camurus Ab Opioidų vaisto formos
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071246A2 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR CONTROLLED RELEASE OF ANALGESICS TO TREAT POSTOPERATIVE PAIN, AND DEVICES, SYSTEMS, AND RELATED METHODS
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
WO2022175974A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
EP0625069B1 (de) 1992-10-26 1998-12-30 Schwarz Pharma Ag Verfahren zur herstellung von mikrokapseln
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
DE69524398T2 (de) 1994-04-08 2002-07-18 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
EP0704206B1 (de) 1994-09-30 2002-09-04 MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH Pharmazeutische Zusammensetzung
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2231273A1 (en) 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030003144A1 (en) 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
EP2561860B1 (en) 2002-05-31 2018-02-28 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
EP1682091B1 (en) 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005020359D1 (de) * 2005-01-14 2010-05-12 Camurus Ab Topische bioadhäsive formulierungen
JP5107725B2 (ja) * 2005-01-14 2012-12-26 カムルス エービー ＧｎＲＨ類似体製剤
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CN102307895A (zh) 2008-12-04 2012-01-04 里兰斯坦福初级大学理事会 用于治疗或预防麻醉药停药症状的方法和组合物
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
PL2611445T3 (pl) 2010-09-03 2018-12-31 Zoetis Belgium S.A. Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego
EA036213B1 (ru) 2011-05-25 2020-10-14 Камурус Аб Пептидные композиции с контролируемым высвобождением
EP2787975B1 (en) 2011-12-05 2017-10-04 Camurus AB Robust controlled-release formulations
LT2877155T (lt) 2012-07-26 2021-02-25 Camurus Ab Opioidų vaisto formos
CN104661648B (zh) 2012-07-26 2019-04-05 卡姆拉斯公司 阿片样物质制剂
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US11920160B2 (en) 2013-02-22 2024-03-05 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
KR102505642B1 (ko) 2013-03-15 2023-03-06 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
US20180244592A1 (en) 2015-10-28 2018-08-30 Haldor Topsøe A/S Dehydrogenation of ethylbenzene to styrene
AU2019357036B2 (en) 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression

Also Published As

Publication number Publication date
NZ704012A (en) 2017-09-29
BR112015001548A2 (pt) 2017-07-04
HRP20210068T1 (hr) 2021-03-05
CN109010255A (zh) 2018-12-18
CN109010255B (zh) 2022-10-21
NZ735248A (en) 2018-10-26
SG10201703964TA (en) 2017-06-29
AU2017279657B2 (en) 2018-11-15
US20240131021A1 (en) 2024-04-25
AU2016244271A1 (en) 2016-10-27
PT2877155T (pt) 2020-12-18
MX361873B (es) 2018-12-18
IL296882A (en) 2022-12-01
SG11201500554XA (en) 2015-02-27
HK1205948A1 (en) 2015-12-31
CL2015000197A1 (es) 2015-11-13
AU2017279657A1 (en) 2018-01-18
JP2015522649A (ja) 2015-08-06
US20250049783A1 (en) 2025-02-13
AU2019200982A1 (en) 2019-02-28
ES2837803T3 (es) 2021-07-01
JP6417327B2 (ja) 2018-11-07
EA201590202A1 (ru) 2015-07-30
EA034855B1 (ru) 2020-03-30
AU2016244271B2 (en) 2018-01-18
DK2877155T3 (da) 2021-01-18
CY1124016T1 (el) 2022-05-27
US12161640B2 (en) 2024-12-10
IL289157A (en) 2022-02-01
HK1221636A1 (zh) 2017-06-09
MY189481A (en) 2022-02-16
IL236762A0 (en) 2015-03-31
AU2019200982B2 (en) 2019-07-18
US20240075024A1 (en) 2024-03-07
US20240226091A9 (en) 2024-07-11
MX2015001033A (es) 2015-04-09
LT2877155T (lt) 2021-02-25
HUE053273T2 (hu) 2021-06-28

Similar Documents

Publication Publication Date Title
CO7190238A2 (es) Formulaciones de opioides
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
PE20150672A1 (es) Formulaciones de opioides
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
ECSP13012499A (es) Nuevos compuestos
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
CL2017001024A1 (es) Formulación de buprenorfina inyectable
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP15013883A (es) Benzamidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20160462A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
PE20150928A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
ES2531312T3 (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos
DOP2013000004A (es) Agentes terapeuticos 976
NI201400066A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la libración del principio activo, útil como anticonceptivo de uso continuo en mujeres
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
MX360531B (es) Formulación de aroma y fragancia (ii).
MX2015004315A (es) Formulacion de aroma y fragancia (vi).
CO7160072A2 (es) Síntesis de compuestos heterocíclicos
CO7131364A2 (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres
DOP2014000142A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberación del principio activo, útil como anticonceptivo de uso continuo en mujeres

Legal Events

Date Code Title Description
FG Grant, registration